The latest update is out from BriaCell Therapeutics Corp (BCT).
BriaPro Therapeutics Corp., majorly owned by BriaCell Therapeutics Corp., recently disclosed its unaudited financial performance for the first half of the fiscal year, ending January 31, 2024. These reports, which offer a glimpse into the subsidiary’s financial health and strategic direction, are now publicly available for review by investors and regulators but are not considered officially filed under securities law. This release aims to provide transparency to shareholders and the market without imposing legal liability on the company for the information provided.
See more insights into BCT stock on TipRanks’ Stock Analysis page.
